Stanford Consortium Wins $40 Million to Create Stem Cell Genomics Center
By David Jensen,
California Stem Cell Report
| 01. 29. 2014
Directors of the California stem cell agency today approved a $40 million proposal ultimately targeted at creating medical treatments tailored to a patient's genetic makeup and making the state a world leader in stem cell genomics.
The proposal by a seven-member consortium led by Stanford University was approved on a 6-1 vote of the 29-member board. Most of those not voting were disqualified because of conflicts of interest.
The action came despite charges by Stanford's competitors that the grant review process was tainted by unfairness, apparent preferential treatment and manipulation of scientific scores.
The award is the largest research grant that the agency has made in its nine-year history although the cash is being divided among the seven participants over five years.
The board added $7 million to the Stanford award to help possibly fund proposals from institutions that lost out in the round. They would have to apply to the consortium, which might have their own proposals in the same areas already underway.
The stem cell agency has high hopes for the genomics project, which is supposed to provide...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...